跳至主要内容
临床试验/NCT03906578
NCT03906578进行中(未招募)不适用

Effect of a Probiotic on Blood Pressure in Low-to-moderate Risk Grade 1 Hypertension - a Randomized Study

Charite University, Berlin, Germany2 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2019年9月2日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
46
试验地点
2
主要终点
Nocturnal systolic blood pressure

研究概览

简要总结

High blood pressure is a major risk factor for cardiovascular events, including stroke, heart and kidney failure. Typical anti-hypertensive drugs target vessels, the kidneys or the heart. Here we propose a randomized, placebo-controlled study to test the blood pressure-lowering effect of a probiotic in 110 patients with grade 1 hypertension. In addition, we will investigate glucose variability, fecal bacterial metabolome, peripheral blood effector T cell frequencies (%) and health-related quality of life.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
50 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men and postmenopausal women
  • Treated or untreated hypertension (resting office blood pressure 130-159/80-99 mmHg)
  • BMI 18.5 - 34.9 kg/m^2

排除标准

  • Secondary causes of hypertension
  • Known target organ damage
  • 10 years cardiovascular risk score of >20%
  • Established cardiovascular or renal disease
  • Other serious diseases
  • Recent use of antibiotics
  • Specialized diets, e.g. use of probiotics
  • Two inclusion criteria were changed in June 2021 to improve recruitment
  • Age was changed from 50-75 to 50-80 years
  • Resting blood pressure was changed from 140-159/90-99 to 130-159/80-99 mmHg

结局指标

主要结局

Nocturnal systolic blood pressure

时间窗: After 8 weeks compared to placebo and adjusted to baseline

Measured by 24h ABPM (mmHg)

次要结局

  • Office systolic blood pressure(After 8 weeks compared to placebo and adjusted to baseline)
  • Nocturnal diastolic blood pressure(After 8 weeks compared to placebo and adjusted to baseline)
  • 24h systolic blood pressure(After 8 weeks compared to placebo and adjusted to baseline)
  • 24h diastolic blood pressure(After 8 weeks compared to placebo and adjusted to baseline)
  • Change in immune cell phenotypes(After 8 weeks compared to placebo and adjusted to baseline)
  • PROMIS-29 domain physical function(After 8 weeks compared to placebo and adjusted to baseline)
  • PROMIS-29 domain fatigue(After 8 weeks compared to placebo and adjusted to baseline)
  • PROMIS-29 domain ability to participate in social roles and activities(After 8 weeks compared to placebo and adjusted to baseline)
  • Office diastolic blood pressure(After 8 weeks compared to placebo and adjusted to baseline)
  • Gut microbiome(After 8 weeks compared to placebo and adjusted to baseline)
  • PROMIS-29 domain depression(After 8 weeks compared to placebo and adjusted to baseline)
  • PROMIS-29 domain anxiety(After 8 weeks compared to placebo and adjusted to baseline)
  • Reduction of antihypertensive medication(After 8 weeks compared to placebo and adjusted to baseline)
  • Glucose variability after standardized breakfasts(After 8 weeks compared to placebo and adjusted to baseline)
  • Metabolomics stool and serum(After 8 weeks compared to placebo and adjusted to baseline)
  • PROMIS-29 domain pain interference(After 8 weeks compared to placebo and adjusted to baseline)
  • PROMIS-29 domain sleep disturbance(After 8 weeks compared to placebo and adjusted to baseline)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kristin Kraeker

Principal Investigator

Charite University, Berlin, Germany

研究点 (2)

Loading locations...

相似试验

Effects of a Probiotic in Hypertension | 临床试验